

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1999PLC056594

Ref: STEX/OUTCOME/2020-21

Date: 12.02.2021

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended on December 31, 2020.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2020 as **Annexure-A** and
- Limited Review Report on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- The agreement dated 17.09.2019 which was entered between Medicamen Biotech Limited and Baxyran Healthcare Private Limited has been revoked, mutually decided by the parties and as a result Medicamen Biotech Limited shall remain 100% Shareholder of the Opal Pharmaceuticals Pty Ltd.
- Our state of art US FDA compliant Oncology Plant at Haridwar shall start taking plant validations of Oncology products from 24th February, 2021.

The meeting of the Board of Directors commenced 2.00 p.m. and concluded at 3.15 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2020, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157





MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Annexure-A

Unaudited Standalone and Consolidated Financial Results for the quarter and Nine Months ended on 31st Dec' 2020

PART I	Rupees in Lacs (Except per Share Data)												
	Standalone						Consolidated						
	Quarter Ended			Nine Months Ended			Quarter Ended			Nine Months Ended			
	3 Months Ended 31.12.2020	Preceding 3 Months Ended 30.09.2020	Corresponding 3 Months Ended 31.12.2019	31st Dec' 2020	31st Dec' 2019	31.03.2020	3 Months Ended 31.12.2020	Preceding 3 Months Ended 30.09.2020	Corresponding 3 Months Ended 31.12.2019	31st Dec' 2020	31st Dec' 2019	31.03.2020	
Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited		
1	Income from operations												
	(a) Net Sales /Income from operations	3,292.20	3,071.19	3,533.49	8,980.91	10,197.91	11,734.23	3,292.20	3,077.19	3,533.49	9,147.73	10,197.91	12,550.38
	(b) Other Income	0.08	13.19	45.07	21.58	84.20	190.86	0.08	13.19	45.07	21.58	84.20	193.88
	(c) Total Revenue	3,292.28	3,090.38	3,578.56	9,002.59	10,282.11	11,925.09	3,292.28	3,090.38	3,578.56	9,169.41	10,282.11	12,744.26
2	Expenses												
	a) Cost of Material Consumed	2,043.65	1,910.52	2,160.30	5,610.81	6,505.04	7,449.16	2,043.65	1,910.52	2,160.30	5,751.93	6,505.04	8,045.29
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in Inventory of Finished Goods and Work in Progress	176.61	7.62	75.51	222.33	79.74	(153.25)	176.61	7.62	75.51	222.33	79.74	(153.25)
	d) Employees Benefits Expenses	230.86	216.57	263.58	663.64	705.59	929.43	230.86	216.57	263.58	667.35	705.59	952.38
	e) Finance Cost	8.66	37.77	19.10	70.38	56.85	56.85	8.66	37.77	19.10	70.38	56.85	56.85
	f) Depreciation and Amortisation Expenses	71.42	69.85	63.91	210.52	183.24	249.92	71.42	69.85	63.91	210.52	183.24	249.92
	g) Other expenses	315.60	388.43	490.33	1,014.14	1,292.13	1,732.59	315.60	388.43	490.33	1,017.57	1,292.13	1,795.05
	Total Expenses	2,846.80	2,630.36	3,072.73	7,791.82	8,822.59	10,264.71	2,846.80	2,630.36	3,072.73	7,940.08	8,822.59	10,946.24
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	445.48	460.02	505.83	1,210.77	1,459.52	1,660.39	445.48	460.02	505.83	1,229.33	1,459.52	1,798.02
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	445.48	460.02	505.83	1,210.77	1,459.52	1,660.39	445.48	460.02	505.83	1,229.33	1,459.52	1,798.02
6	Tax Expenses												
	Current Year	141.25	135.97	144.36	369.52	405.54	459.52	141.25	135.97	144.36	374.15	405.54	493.93
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	2.76	1.69	(6.47)	6.93	(25.80)	(25.03)	2.76	1.69	(6.47)	6.93	(25.80)	(25.03)
	Total Tax Expense	144.01	137.66	137.89	376.45	379.74	434.49	144.01	137.66	137.89	381.08	379.74	468.90
7	Net Profit /Loss for the period from Continuing operation (5-6)	301.47	322.36	367.94	834.31	1,079.78	1,225.89	301.47	322.36	367.94	848.25	1,079.78	1,329.12
8	Other Comprehensive Income												
	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	301.47	322.36	367.94	834.31	1,079.78	1,225.89	301.47	322.36	367.94	848.25	1,079.78	1,329.12
10	Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66
11	Earning Per Share (Rs.)												
	Basic	2.47	2.54	3.05	6.83	8.94	10.09	2.47	2.64	3.05	6.94	8.94	10.94
	Diluted	2.47	2.54	3.05	6.83	8.94	10.09	2.47	2.64	3.05	6.94	8.94	10.94

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 12th February 2021
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- Our state of art US FDA compliant Oncology Plant at Haridwar shall start taking plant validation of Oncology products from 24th February 2021.
- Due to Covid-19, top line & bottom line have been impacted with the increase in the prices of Raw Materials during the current quarter and Nine Months Ending otherwise gross margins, EBITDA & PAT all on uptrend.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 12.02.2021

For & on behalf of Board of Directors
Medicamen Biotech Limited

(Rahul Bishnoi)
Chairman

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To

The Board of Directors,
Medicamen Biotech Ltd.
 1506, Chiranjiv Tower, 43,
 Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended December 31, 2020 and the year to date results for the period April 01, 2020 to December 31, 2020 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
 Chartered Accountants


Qimat Rai Garg
 Partner
 (Membership Number: 013152C)
 UDIN: 21080857AAAAAS6889

Place: Gurugram
 Date: 12.02.2021

INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To

**The Board of Directors,
Medicamen Biotech Limited
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019**

1. We have reviewed the Unaudited Consolidated Financial Results of Medicamen Biotech Limited (the "Parent Company"), and the Subsidiary Company for the quarter & nine months ended on December 31, 2020 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter ended December 31, 2020 and the year to date results for the period April 01, 2020 to December 31, 2020 (the "Statement")'. The Statement is being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd (the "Subsidiary" Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to

be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Consolidated Unaudited Financial Results also includes the Group's share of net profit after tax of Rs. 13.94 Lakhs for the quarter and nine months ended December 31, 2020, as considered in the consolidated unaudited financial results, in respect of an subsidiary, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 013152C)
UDIN:- 21080857AAAAAT1939

Place: Gurugram
Date: 12.02.2021